Haleon PLC

Major Shareholding Notification • May 20, 2024

National Storage Mechanism | Additional information

RNS Number : 1477P

Haleon PLC

20 May 2024

20 May 2024

HALEON PLC  

("Haleon" or "the Company")   

TR-1: Standard form for notification of major holdings  

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :			Haleon plc
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name			GSK plc
City and country of registered office (if applicable)			London, England
4. Full name of shareholder(s) (if different from 3.) v
Name			Vidacos Nominees Limited
City and country of registered office (if applicable)			London, England
5. Date on which the threshold was crossed or reached vi :			17/05/2024
6. Date on which issuer notified (DD/MM/YYYY):			20/05/2024
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached	0	0		0	0
Position of previous notification (if applicable)	4.17	0		4.17

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
Direct (DTR5.1)		Indirect  (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
GB00BMX86B70		0		0			0		0
SUBTOTAL 8. A		0					0
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash Settlement xii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
GSK plc (Chain 1)	0		0
GlaxoSmithKline Holdings Limited (Chain 1)	0		0
GlaxoSmithKline Finance plc (Chain 1)	0		0
Glaxo Group Limited (Chain 1)	0		0
GSK plc (Chain 2)	0		0
GSK LP Limited (Chain 2)	0		0
GSK GP 1 Limited (Chain 2)	0		0
GSK (No.1) Scottish Limited Partnership (Chain 2)	0		0
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
This notification relates to the sale by GSK plc (via its indirectly wholly-owned subsidiaries, GSK (No.1) Scottish Limited Partnership and Glaxo Group Limited) of the entirety of its remaining interest in Haleon plc. GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited Partnership.  GSK LP Limited is the sole limited partner of GSK (No.1) Scottish Limited Partnership.  Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership held their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which held the legal title to those shares on their behalf pursuant to a custody arrangement.

Place of completion	London, England
Date of completion	20 May 2024

Amanda Mellor, Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLURSORSUUVUAR